Abstract The expression of glucose transporters (Glut-1, Glut-3), hexokinase-II, and Ki-67 has been proposed to explain intratumoral heterogeneous F-18 fluorodeoxyglucose (FDG) uptake. We report a case of Krukenberg tumor with intratumoral heterogeneous FDG uptake which corresponded well with the expression levels of Glut-1 and ki-67. Fused positron emission tomography (PET)/magnetic resonance (MR) imaging was helpful for localizing the metabolically active area in the tumor specimen. This report elucidates the relationship between the intratumoral heterogeneous FDG uptake and biologic heterogeneity, and shows the usefulness of PET/MR in research on intratumoral heterogeneity.
Introduction
Heterogeneous intratumoral F-18 fluorodeoxyglucose (FDG) uptake is observed in some types of benign and malignant tumors [1, 2] , and Kidd et al. [2] reported that intratumoral metabolic heterogeneity indicates a higher risk of lymph node involvement at diagnosis, poorer response to therapy, and a greater risk of pelvic recurrence in cervical cancer.
Some experiments have been performed to clarify the relation between heterogeneous FDG uptake and biologic heterogeneity, which is known to be related to variations in tumor responsiveness to treatment [3, 4] , degree of vascularity [5] , hypoxia [6] [7] [8] , and tumor cellular metabolism, and intratumoral gene expression [9, 10] . Zhao et al. [11] examined the biologic mechanism responsible for a heterogeneous intratumoral FDG distribution in a rat malignant tumor model, and found that intratumoral FDG distributions corresponded well with the intratumoral expression of glucose transporter 1 (Glut-1), glucose transporter 3 (Glut-3), and hexokinase-II. Thus, they concluded that the expression levels of these proteins might contribute to the degree of FDG accumulation. In addition, Baardwijk et al. [12] reported a correlation between heterogeneous intratumoral FDG uptake and histologic patterns, such as vital tumor and fibrotic regions in human non-small cell lung cancer specimens, but immunohistochemistry was not performed.
Here, we describe a case of a Krukenberg tumor which showed heterogeneous FDG uptake by preoperative FDG positron emission tomography (PET)/computed tomography (CT), in an attempt to elucidate the biologic mechanism responsible for this phenomenon.
Case Report
A 35-year-old woman with resectable advanced gastric cancer underwent subtotal gastrectomy in May 2006 and adjuvant chemotherapy over the following 6 months. However, in December 2009 huge bilateral pelvic masses were revealed during a routine abdominal CT follow-up. The patient was further examined by pelvic magnetic resonance (MR) imaging and a whole-body FDG PET/CT scan and for serum tumor markers, which showed increased CA 19-9 and CA 125 levels [680 U/ml (normal range <37 U/ml) and 69.7 U/ml (normal range <35 U/ml), respectively]. FDG PET/CT was performed using a PET/ CT scanner (Biograph16 Hi-Res, Siemens, Germany). After fasting for at least 6 h, appropriate blood sugar level was checked (<180 mg/dl). Then the patient was injected with 9.25 MBq of FDG per kilogram of body weight, and images were acquired 1 h later. CT was performed for attenuation correction, and subsequently, emission scanning was performed from the skull base to the proximal thigh. Images were reconstructed using an iterative algorithm (ordered-subset expectation maximization). Pelvic MR images showed bilateral ovarian masses of heterogeneous low-signal intensity in T2-weighted images. The masses were mainly solid with multiple small intratumoral cysts, and lobulated but smooth margins. These right and left ovarian masses had maximum diameters of 12.5 cm and 5.2 cm, respectively. After injection of gadolinium-based contrast agent, the masses showed strong enhancement. (Fig. 1a-c) .
In whole-body PET/CT images, the bilateral ovarian masses showed mildly increased metabolic activity with a focal markedly active portion in the anterior region of the right ovarian mass (Fig. 1d) . The maximum SUV (SUVmax) of the most metabolically active portion was 6.8. On the other hand, the other part of both ovarian masses showed relatively mild FDG uptake (SUVmax 2.1). However, this metabolically active area did not show stronger gadolinium enhancement in MR image than other areas of the tumor (Fig. 1c) .
The patient underwent bilateral salpingo-oophorectomy, and the pathologic diagnosis was of metastatic adenocarcinoma from gastric cancer. To investigate the biologic mechanism responsible for the heterogeneous FDG uptake, pathologic specimens were re-reviewed. No necrotic region or residual ovarian tissue was observed in the gross specimen of the right ovarian mass. To identify the precise location of the most metabolically active area in the right tumor specimen, we matched the T2-weighted coronal MR image with the gross specimen ( Fig. 2a, b) . We performed software-based image fusion of MR coronal images and FDG PET images (Fig. 2a linearity of the hip margin. After verification, the most metabolically active area (MG1) and four other tumor regions (MG2-MG5) of the right-side tumor were selected (Fig. 2b) . The SUVmax of these five regions were 6.8, 2.1, 1.7, 2.1, and 1.9, respectively.
To elucidate the biologic mechanism underlying the heterogeneous FDG uptake, we initially compared tumor cellularities in the five tumor regions. However, no significant difference was found. Immunostaining for Ki-67, Glut-1, hexokinase-II, and CD31 were performed in each tumor region sampled. Table 1 summarizes (Fig. 5a, b) . On the contrary, the immunoreactive level of hexokinase-II and MVD of the five tumor regions showed no significant correlation with SUVmax (P=n.s., P=n.s.) (Fig. 5c, d) . was done by MedCalc (MedCalc Software). P values of less than 0.05 were considered significant.
Discussion
Focal high intratumoral FDG uptake can be caused by either a nonmalignant component in the tumor or heterogeneity of a malignant component within the tumor. For a nonmalignant component, the area of intratumoral necrosis is the most common cause of focal high intratumoral FDG uptake. The reason for high FDG accumulation in necrotic regions is mainly due to macrophage aggregation, caused by active inflammation [14] . Other causes of nonmalignant high intratumoral FDG uptake include a residual ovary which may contain functional cysts or corpus luteum in patients with primary or metastatic ovarian tumors [15] . Heterogeneity within the malignant component of the tumor-for example, heterogeneous intratumoral cell proliferation, or regional hypoxia-can also cause heterogeneous intratumoral FDG uptake [16] . Immunostaining has often been used to investigate these phenomena-for example, Ki-67 is known to reflect tumor proliferation [17, 18] , HIF-1α is known to be related to hypoxic conditions [19] , and Glut-1, Glut-3, and hexokinase-II are known to be related to increased glucose utilization [11, 19] . Accordingly, many studies have shown that SUVmax values are correlated with the expression of Glut-1, Glut-3, hexokinase, and Ki-67 in malignant tumors [17, 19] . However, the heterogeneous intratumoral expression of these proteins, causing focal high SUVmax, have not been previously reported in human cases. In the present study, we demonstrate that intratumoral heterogeneous FDG uptake corresponds with the level of expression of Ki-67 and Glut-1 through image-pathology correlation. However, whether the immunostaining sites correspond exactly to the areas showing the intratumoral heterogeneity in FDG uptake may be a possible limitation.
We also immunostained for CD31, the expression of which is known to be correlated with microvessel density, which in turn, reflects tumor angiogenesis. However, no significant correlation was observed between MVD and SUVmax. This is consistent with the findings of a previous study, which found no positive correlation between FDG uptake and microvessel density [20] .
As shown by this report, Glut-1 and Ki-67 expression levels may vary widely even in a single tumor with heterogeneous FDG uptake. Several studies have reported a correlation between SUVmax and protein expression in tumors of different patients [17, 19] . However, in these studies, no mention was made of the locations of these proteins expressed in one tumor.
Finally, we performed PET/MR image fusion to locate the hypermetabolic focus precisely on tumor specimens. MR imaging is superior to CT with respect to tumor delineation and soft tissue contrast [21, 22] , and thus, MR , immunoreactive level of hexokinase-II (P = n.s., c), and MVD (P = n.s., d). HK-II hexokinase-II imaging is more feasible than CT in terms of matching with tumor specimens and radiologic images. Thus, a fused PET/ MR image was more beneficial than a fused PET/CT image in locating a focal hypermetabolic area in the tumor specimen in our case.
Conclusion
Intratumoral heterogeneous FDG uptake was found to correspond well with Glut-1 and ki-67 expression in a Krukenberg tumor. Furthermore, our findings show that Glut-1 and Ki-67 levels may vary widely even in a single tumor that shows heterogeneous FDG uptake. In addition, PET/MR fusion imaging enabled us to localize a metabolically active area on a tumor specimen.
